Payment overview · 2025
General Payments
$356.90
7 reported records · 4 companies
Healthcare provider profile · identity verified
Michael David Smith, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LANGHORNE, PA · NPI 1992760219
Verified facts
What the public records show
CMS Open Payments records show Michael David Smith, D.O. received $356.90 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 70.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $252.74 | 70.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.60 | 17.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.52 | 6.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.04 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $356.90 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $63.60 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $63.60 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $63.60 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 52 |
| Omeprazole | Omeprazole | 184 | 47 |
| Lisinopril | Lisinopril | 171 | 48 |
| Gabapentin | Gabapentin | 156 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 42 |
| Furosemide | Furosemide | 135 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 34 |
| Losartan Potassium | Losartan Potassium | 127 | 36 |
| Meloxicam | Meloxicam | 126 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 32 |
| Metformin Hcl | Metformin Hcl | 122 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 56 |
| Sertraline Hcl | Sertraline Hcl | 117 | 31 |
| Simvastatin | Simvastatin | 116 | 32 |
| Prednisone | Prednisone | 115 | 85 |
| Farxiga | Dapagliflozin Propanediol | 114 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 30 |
| Carvedilol | Carvedilol | 92 | 21 |
| Januvia | Sitagliptin Phosphate | 92 | 15 |
| Lorazepam | Lorazepam | 92 | 14 |
| Trazodone Hcl | Trazodone Hcl | 91 | 26 |
| Metformin Hcl Er | Metformin Hcl | 90 | 23 |
| Alprazolam | Alprazolam | 89 | 19 |
| Tramadol Hcl | Tramadol Hcl | 89 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 22 |
| Glimepiride | Glimepiride | 83 | 22 |
| Synthroid | Levothyroxine Sodium | 83 | 21 |
| Jardiance | Empagliflozin | 81 | 17 |
| Montelukast Sodium | Montelukast Sodium | 76 | 21 |
| Ozempic | Semaglutide | 75 | 15 |
| Amoxicillin | Amoxicillin | 72 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 17 |
| Valsartan | Valsartan | 61 | 16 |
| Azithromycin | Azithromycin | 60 | 52 |
| Famotidine | Famotidine | 60 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 17 |
| Atenolol | Atenolol | 56 | 14 |
| Eliquis | Apixaban | 53 | 11 |
| Potassium Chloride | Potassium Chloride | 53 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 13 |
| Celecoxib | Celecoxib | 45 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Ramipril | Ramipril | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Tadalafil | Tadalafil | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 14 |
| Cephalexin | Cephalexin | 30 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 17 |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Desloratadine | Desloratadine | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $356.90 · 7 records | Amgen Inc. | ABRYSVO, BOTOX, COMIRNATY, OTEZLA, PREVNAR 20, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error